ASX:NC6

Nanollose Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume516,254 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive NC6 News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanollose and its competitors with MarketBeat's FREE daily newsletter.

About Nanollose

Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It focuses on the development of Nullarbor, a plant-free viscose-rayon fibre. The company's products are used in textiles, nonwoven fabric, and other industries. Nanollose Limited was founded in 2014 and is based in Nedlands, Australia.

Here's Why We're A Bit Worried About Nanollose's (ASX:NC6) Cash Burn Situation
October 13, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:NC6
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.nanollose.com
Phone: 61 8 9389 3120
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $322,859.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 3.15
Book Value: A$0.02 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 1.32
Current Ratio: 6.10
Quick Ratio: 5.99

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.85 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Nanollose.

4.3 Community Rank

Outperform Votes
Nanollose has received 12 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Nanollose has received 7 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Nanollose has received 63.16% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Nanollose and other stocks. Vote “Outperform” if you believe NC6 will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NC6 will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Nanollose does not currently pay a dividend.
Dividend Growth
Nanollose does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nanollose insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Nanollose (ASX:NC6) Frequently Asked Questions

What stocks does MarketBeat like better than Nanollose?: Wall Street analysts have given Nanollose a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nanollose wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are Nanollose's key executives?: Nanollose's management team includes the following people:
Dr. Wayne Morris Best, Exec. Chairman
Ms. Erlyn Saromines Dale A.C.I.S., B.Com., BCom., GradDipACG, AGIA, ACIS, Company Sec.
Who are some of Nanollose's key competitors?: Some companies that are related to Nanollose include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of NC6's competitors.
What is Nanollose's stock symbol?: Nanollose trades on the ASX under the ticker symbol "NC6."
How much money does Nanollose make?: Nanollose has a market capitalization of $0.00 and generates $322,859.00 in revenue each year.
What is Nanollose's official website?: The official website for Nanollose is www.nanollose.com.
How can I contact Nanollose?: The company can be reached via phone at 61 8 9389 3120.

This page was last updated on 10/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.